AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29045800 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading group (n = 77)
Number of subjects: 158
Study 29045800 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 158
Study 29045800 — intervention group
Group type: COMPARATOR
Intervention: Immediate loading group vs Delayed loading group
Number of subjects: 158
Study 27123977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy based on the catastrophic cognitions model of PDA
Number of subjects: 46
Study 27123977 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mastery (guided exposure) therapy based on the self-efficacy model of PDA
Number of subjects: 46
Study 27123977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 46
Study 27123977 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 46
Study 25161302 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral targeted nebulization
Number of subjects: 6
Study 25161302 — intervention group
Group type: COMPARATOR
Intervention: Central targeted nebulization
Number of subjects: 6
Study 22198639 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week once-a-week prolonged strength-training programme
Number of subjects: 95
Study 22198639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 95
Study 20142220 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute stent
Number of subjects: 139
Study 18499791 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cerebral microbleeds in patients with ICH
Number of subjects: 87
Study 18499791 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of microbleeds in patients with ICH
Number of subjects: 87
Study 18499791 — intervention group
Group type: EXPERIMENTAL
Intervention: INR levels in patients with ICH
Number of subjects: 87
Study 18499791 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of hypertension in patients with ICH
Number of subjects: 87
Study 18499791 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cerebral microbleeds as a risk factor for ICH
Number of subjects: 87
Study 16129216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 12167391 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959
Study 12167391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959
Study 9892856 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg/day)
Number of subjects: 323
Study 9892856 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine (200 mg/day)
Number of subjects: 323
Study 9892856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 9892856 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 323
Study 9892856 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine
Number of subjects: 323
Study 7585283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 90
Study 7585283 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus cholestyramine
Number of subjects: 90
Study 7585283 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac care
Number of subjects: 90
Study 2272192 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg etizolam
Number of subjects: 30
Study 2272192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7026401 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal-systemic shunt (PSS)
Number of subjects: 53
Study 7026401 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 53
Study 31852444 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF)
Number of subjects: 271
Study 31852444 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF)
Number of subjects: 271
Study 31852444 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 271
Study 28698258 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban
Number of subjects: 1000
Study 28698258 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose enoxaparin
Number of subjects: 1000
Study 26408319 — intervention group
Group type: EXPERIMENTAL
Intervention: Yerba Mate supplementation (3 g/day, 3 capsules per meal, 3 times a day for 12 weeks)
Number of subjects: 30
Study 26408319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23506627 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual protein/creatinine ratio (rPCR) <1000 mg/g
Number of subjects: 1245
Study 23506627 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual estimated glomerular filtration rate (reGFR) ≥45 mL/min per 1.73 m2
Number of subjects: 1245
Study 23506627 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual protein/creatinine ratio (rPCR) between 1000-<2000 mg/g and reGFR ≥30 mL/min per 1.73 m2
Number of subjects: 1245
Study 23506627 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual estimated glomerular filtration rate (reGFR) <30 mL/min per 1.73 m2 and rPCR ≥2000 mg/g
Number of subjects: 1245
Study 21946475 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training (group A)
Number of subjects: 95
Study 21946475 — intervention group
Group type: EXPERIMENTAL
Intervention: Group training (group B)
Number of subjects: 95
Study 21946475 — intervention group
Group type: COMPARATOR
Intervention: Self-learning (group C)
Number of subjects: 95
Study 19445552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual morphine sulphate 0.5 mg/kg (Group A)
Number of subjects: 29
Study 19445552 — intervention group
Group type: COMPARATOR
Intervention: Sublingual midazolam 0.03 mg/kg (Group B)
Number of subjects: 29
Study 18508950 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 5 mg once daily for 14 days
Number of subjects: 60
Study 18508950 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 7.5 mg once daily for 14 days
Number of subjects: 60
Study 18508950 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 10 mg once daily for 14 days
Number of subjects: 60
Study 18508950 — intervention group
Group type: EXPERIMENTAL
Intervention: Taranabant 25 mg once daily for 14 days
Number of subjects: 60
Study 16077888 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics and G-CSF (group A)
Number of subjects: 35
Study 16077888 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics only (group B)
Number of subjects: 35
Study 11849419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal peritoneal dialysis (TPD)
Number of subjects: 87
Study 11849419 — intervention group
Group type: COMPARATOR
Intervention: Continuous equilibrating peritoneal dialysis (CEPD)
Number of subjects: 87
Study 11849419 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD
Number of subjects: 87
Study 11849419 — intervention group
Group type: COMPARATOR
Intervention: CEPD
Number of subjects: 87
Study 11849419 — intervention group
Group type: EXPERIMENTAL
Intervention: Kt/V
Number of subjects: 87
Study 10215975 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psycho-educational intervention (PEI) facilitated by a nurse in the community, three sessions
Number of subjects: 252
Study 7484022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 50-80 micrograms.kg-1.min-1
Number of subjects: 26
Study 7484022 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg.kg-1
Number of subjects: 26
Study 7484022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 50 micrograms.kg-1.min-1 + Morphine 0.1 mg.kg-1
Number of subjects: 26
Study 7484022 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 0.1 mg.kg-1
Number of subjects: 26
Study 2198848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrease
Number of subjects: 39
Study 2198848 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon
Number of subjects: 39
Study 364021 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimycotic denture adhesive (amphotericin medicated adhesive)
Number of subjects: 70
Study 364021 — intervention group
Group type: COMPARATOR
Intervention: Placebo denture adhesive
Number of subjects: 70
Study 31556001 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 152
Study 31556001 — intervention group
Group type: COMPARATOR
Intervention: CVC
Number of subjects: 152
Study 30203412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 22
Study 30203412 — intervention group
Group type: COMPARATOR
Intervention: Uncemented total hip arthroplasty
Number of subjects: 22
Study 28327696 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mm subcrestal implant placement
Number of subjects: 60
Study 28327696 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mm subcrestal implant placement
Number of subjects: 60
Study 25833966 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdecompression
Number of subjects: 885
Study 25833966 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 885
Study 22806557 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program
Number of subjects: 33152
Study 22806557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33152
Study 21335622 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 1089
Study 21335622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1089
Study 19126187 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rapid rate lumbosacral magnetic stimulation (rLSMS) at 15 Hz, 100% output intensity for 5 s min(‐1) for 30 min
Number of subjects: 12
Study 19126187 — intervention group
Group type: COMPARATOR
Intervention: Sham rapid rate lumbosacral magnetic stimulation (rLSMS)
Number of subjects: 12
Study 19126187 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rapid rate lumbosacral magnetic stimulation (rLSMS)
Number of subjects: 12
Study 17531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous preterm birth
Number of subjects: 0
Study 17531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated preterm birth
Number of subjects: 0
Study 17531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors modifying risk
Number of subjects: 0
Study 15533378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (Dextran 40) infusion
Number of subjects: 0
Study 15533378 — intervention group
Group type: COMPARATOR
Intervention: Human albumin infusion
Number of subjects: 0
Study 11486851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum assisted drainage (Group A)
Number of subjects: 50
Study 11486851 — intervention group
Group type: COMPARATOR
Intervention: Centrifugal pump venous aspiration (Group B)
Number of subjects: 50
Study 9623383 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case management
Number of subjects: 100
Study 9623383 — intervention group
Group type: COMPARATOR
Intervention: Overnight admission
Number of subjects: 100
Study 7839774 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA with propofol and alfentanil (n = 15)
Number of subjects: 30
Study 7839774 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia (BA) with isoflurane/N2O/fentanyl (n = 15)
Number of subjects: 30
Study 2904839 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet alone (Group 1)
Number of subjects: 120
Study 2904839 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo tablet with 150 ml oral fluid (Group 3)
Number of subjects: 120
Study 2904839 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ranitidine 150 mg with oral fluid 150 ml (Group 4)
Number of subjects: 120
Study 2904839 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo tablet with IM narcotic and atropine (Group 2)
Number of subjects: 120
Study 31520294 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutz sedimentation technique
Number of subjects: 213
Study 31520294 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ritchie sedimentation technique
Number of subjects: 213
Study 31520294 — intervention group
Group type: COMPARATOR
Intervention: Faust flotation technique
Number of subjects: 213
Study 31520294 — intervention group
Group type: COMPARATOR
Intervention: Modified Sheather flotation technique
Number of subjects: 213
Study 28652716 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 minutes, for 5 consecutive days)
Number of subjects: 14
Study 28652716 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study 26138864 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 498
Study 26138864 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 498
Study 26138864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 23279720 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 2
Study 23279720 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX-6
Number of subjects: 2
Study 21251087 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual slides
Number of subjects: 10
Study 21251087 — intervention group
Group type: COMPARATOR
Intervention: Glass slides
Number of subjects: 10
Study 21251087 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual microscopy
Number of subjects: 10
Study 18300148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound
Number of subjects: 536
Study 18300148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination by senior pediatric orthopedists
Number of subjects: 536
Study 18300148 — intervention group
Group type: COMPARATOR
Intervention: Graf's method
Number of subjects: 536
Study 17561543 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 15 mg nightly
Number of subjects: 229
Study 17561543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 14563205 — intervention group
Group type: EXPERIMENTAL
Intervention: Halometer device used to detect and quantify halos after LASIK surgery
Number of subjects: 0
Study 14563205 — intervention group
Group type: EXPERIMENTAL
Intervention: Halometer device used with normal subjects
Number of subjects: 0
Study 10981559 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg once daily for 6 weeks
Number of subjects: 0
Study 9108638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 20 mg
Number of subjects: 3
Study 9108638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 40 mg
Number of subjects: 3
Study 9108638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 80 mg
Number of subjects: 3
Study 8251889 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN (human recombinant interferon‐alpha 2a, ROFERON‐A)
Number of subjects: 597
Study 8251889 — intervention group
Group type: EXPERIMENTAL
Intervention: ROFERON‐A for 1 year
Number of subjects: 597
Study 8251889 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 597
Study 3814215 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide, betamethasone 17-valerate, triamcinolone acetonide (alcoholic solutions)
Number of subjects: 14
Study 3814215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol 17-propionate (ointment)
Number of subjects: 14
Study 3814215 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerosene test
Number of subjects: 14
Study 31682163 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screening for ankylosing spondylitis (AS)
Number of subjects: 4916
Study 31682163 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed diagnosis of ankylosing spondylitis (AS)
Number of subjects: 4916
Study 31682163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of ankylosing spondylitis (AS)
Number of subjects: 4916
Study 28678558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine cream
Number of subjects: 40
Study 28678558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27156228 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture alone (A)
Number of subjects: 173
Study 27156228 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine alone (M)
Number of subjects: 173
Study 27156228 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and morphine (AM)
Number of subjects: 173
Study 27156228 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 173
Study 25336916 — intervention group
Group type: COMPARATOR
Intervention: Fimasartan 120 mg (single oral dose)
Number of subjects: 16
Study 24040278 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQL assessments using PedsQL 4.0 Generic Core Scales, PedsQL 3.0 Acute Cancer Module, PedsQL Multidimensional Fatigue Scale, Pediatric Inventory for Parents
Number of subjects: 906
Study 20825523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg) daily for 3 months
Number of subjects: 38
Study 20825523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18315942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost 0.03%/timolol 0.5% administered once daily
Number of subjects: 5
Study 18315942 — intervention group
Group type: COMPARATOR
Intervention: Fixed-combination travoprost/timolol
Number of subjects: 5
Study 18315942 — intervention group
Group type: COMPARATOR
Intervention: Fixed-combination latanoprost/timolol
Number of subjects: 5
Study 15764761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg qd) during 8 weeks of pulmonary rehabilitation (PR)
Number of subjects: 93
Study 15764761 — intervention group
Group type: COMPARATOR
Intervention: Placebo during 8 weeks of pulmonary rehabilitation (PR)
Number of subjects: 93
Study 14706505 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist therapy (immediate adjuvant therapy after prostatectomy)
Number of subjects: 0
Study 14706505 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with radiation
Number of subjects: 0
Study 14706505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (LHRH agonist + nonsteroidal antiandrogen)
Number of subjects: 0
Study 14706505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hormone therapy
Number of subjects: 0
Study 14706505 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist therapy
Number of subjects: 0
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium (females)
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (females)
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium (females)
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium (males)
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (males)
Number of subjects: 108
Study 10998836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium (males)
Number of subjects: 108
Study 8844446 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (1,200 mg every 12 hours)
Number of subjects: 21
Study 8844446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1346794 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12
Study 1346794 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 12
Study 1346794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6835892 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 22
Study 30359684 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg twice daily for seven days
Number of subjects: 200
Study 30359684 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 200
Study 29017535 — intervention group
Group type: EXPERIMENTAL
Intervention: LeucoPatch® device applied in addition to good standard care
Number of subjects: 0
Study 29017535 — intervention group
Group type: COMPARATOR
Intervention: Good standard care (control group)
Number of subjects: 0
Study 29017535 — intervention group
Group type: EXPERIMENTAL
Intervention: LeucoPatch® device
Number of subjects: 0
Study 25840543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration supplemental perioperative oxygen
Number of subjects: 0
Study 25840543 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24121083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SIJ injections
Number of subjects: 120
Study 24121083 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided SIJ injections
Number of subjects: 120
Study 22682323 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times a week
Number of subjects: 92
Study 22682323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 19542193 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message communication (n = 193)
Number of subjects: 402
Study 19542193 — intervention group
Group type: COMPARATOR
Intervention: Card enquiry (n = 209)
Number of subjects: 402
Study 19542193 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message communication
Number of subjects: 402
Study 18076292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (80 mg/12 h)
Number of subjects: 36
Study 18076292 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (250 mg/12 h)
Number of subjects: 36
Study 18076292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18076292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 36
Study 15044399 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 139